Thomas indicated that the synergies with the MRI and laboratory systems manufacturer do not sufficiently warrant a capital investment of 45 billion euros ($46.91 billion), which reflects the value of Siemens' 75% stake.
"We are evaluating the economic opportunities for Siemens AG in the healthcare sector. We will then derive from this how instrumental Healthineers is as an investment. And then we will draw a conclusion from that," he explained, noting that findings will be shared during a capital markets day scheduled for late 2025.
Siemens AG had previously spun off the Erlangen-based subsidiary in 2018 and listed it on the stock market. Until now, the company had expressed intentions to retain its majority stake in Siemens Healthineers.
However, Thomas recently suggested the possibility of divesting approximately 5% in the near future to fund the acquisition of U.S. software firm Altair.
He also reaffirmed his commitment to the Mobility train division, despite ongoing calls from investors for its separation. "The business is in good hands with us. I don't see any need for us to part with it at the moment," he told Handelsblatt.